Answers are grounded in this paper and cite their sources.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) improved survival in appropriately selected patients with peritoneal carcinomatosis. Guideline recommendations are important for its promotion. However, this treatment is not performed widely in Japan. The disparity in practice may be reflected in the national guidelines. Recommendations were compared between 5 sets of guidelines each in Western countries and Japan. 1) The role of CRS was established for colorectal and ovarian cancers whereas that of HIPEC was controversial in Western countries. On the other hand, neither was recommended for colon cancer, and HIPEC was recommended only in research for ovarian cancer in Japan. 2) Potential effects in a limited cases were recognized for gastric cancer in the Western guidelines. 3) Resection for localized metastasis for colon cancer and intraperitoneal chemotherapy for ovarian and gastric cancers were recommended in Japan instead of CRS+HIPEC. 4) CRS+HIPEC is recommended as a first-line treatment for pseudomyxoma peritonei and peritoneal mesothelioma in Western countries but recommended only for pseudomyxoma in Japan. There is a disparity in the guidelines for CRS+HIPEC, which is attributed to not being widely performed in Japan. Synopsis The disparity in practice may be reflected in the national guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Recommendations were towards to more negative in Japan than in Western countries. This is attributed to not being widely performed in Japan. It is necessary to achieve social consensus on this treatment.
No takes yet. Share an insight, caveat, or question.
Kitai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: